34856889|t|Destabilization of Abeta fibrils by omega-3 polyunsaturated fatty acids: a molecular dynamics study.
34856889|a|The senile plaques of neurotoxic aggregates of Abeta protein, deposited extraneuronally, mark the pathological hallmark of Alzheimer's disease (AD). The natural compounds such as omega-3 (omega-3) polyunsaturated fatty acids (PUFAs), which can access blood-brain barrier, are believed to be potential disruptors of preformed Abeta fibrils to cure AD with unknown mechanism. Herein, we present the destabilization potential of three omega-3 PUFAs, viz. Eicosapentaenoic acid (EPA), Docosahexaenoic acid (HXA), and alpha-linolenic acid (LNL) by molecular dynamics simulation. After an initial testing of 300 ns, EPA and HXA have been considered further for extended production run time, 500 ns. The increased value of root mean square deviation (RMSD), radius of gyration, and solvent-accessible surface area (SASA), the reduced number of H-bonds and beta-sheet content, and disruption of salt bridges and hydrophobic contacts establish the binding of these ligands to Abeta fibril leading to destabilization. The polar head was found to interact with positively charged lysine (K28) residue in the fibril. However, the hydrophobicity of the long aliphatic tail competes with the intrinsic hydrophobic interactions of Abeta fibril. This amphiphilic nature of EPA and HXA led to the breaking of inherent hydrophobic contacts and formation of new bonds between the tail of PUFA and hydrophobic residues of Abeta fibril, leading to the destabilization of fibril. The Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) results explain the binding of EPA and HXA to Abeta fibril by interacting with different residues. The destabilization potential of EPA and HXA establishes them as promising drug leads to cure AD, and encourages prospecting of other fatty acids for therapeutic intervention in AD.Communicated by Ramaswamy H. Sarma.
34856889	19	24	Abeta	Gene	351
34856889	36	71	omega-3 polyunsaturated fatty acids	Chemical	-
34856889	123	133	neurotoxic	Disease	MESH:D020258
34856889	148	153	Abeta	Gene	351
34856889	224	243	Alzheimer's disease	Disease	MESH:D000544
34856889	245	247	AD	Disease	MESH:D000544
34856889	280	325	omega-3 (omega-3) polyunsaturated fatty acids	Chemical	-
34856889	327	332	PUFAs	Chemical	MESH:D005231
34856889	426	431	Abeta	Gene	351
34856889	448	450	AD	Disease	MESH:D000544
34856889	533	546	omega-3 PUFAs	Chemical	-
34856889	553	574	Eicosapentaenoic acid	Chemical	MESH:D015118
34856889	576	579	EPA	Chemical	MESH:D015118
34856889	582	602	Docosahexaenoic acid	Chemical	MESH:D004281
34856889	604	607	HXA	Gene	280
34856889	614	634	alpha-linolenic acid	Chemical	MESH:D017962
34856889	636	639	LNL	Chemical	MESH:D017962
34856889	711	714	EPA	Chemical	MESH:D015118
34856889	719	722	HXA	Gene	280
34856889	1068	1073	Abeta	Gene	351
34856889	1317	1322	Abeta	Gene	351
34856889	1358	1361	EPA	Chemical	MESH:D015118
34856889	1366	1369	HXA	Gene	280
34856889	1470	1474	PUFA	Chemical	MESH:D005231
34856889	1503	1508	Abeta	Gene	351
34856889	1655	1658	EPA	Chemical	MESH:D015118
34856889	1663	1666	HXA	Gene	280
34856889	1670	1675	Abeta	Gene	351
34856889	1756	1759	EPA	Chemical	MESH:D015118
34856889	1764	1767	HXA	Gene	280
34856889	1817	1819	AD	Disease	MESH:D000544
34856889	1857	1868	fatty acids	Chemical	MESH:D005227
34856889	1901	1916	AD.Communicated	Disease	MESH:D000544
34856889	Association	MESH:D000544	351
34856889	Negative_Correlation	MESH:D000544	280
34856889	Negative_Correlation	280	351
34856889	Negative_Correlation	MESH:D015118	MESH:D000544
34856889	Negative_Correlation	MESH:D005231	MESH:D000544
34856889	Negative_Correlation	MESH:D015118	351
34856889	Negative_Correlation	MESH:D005231	351

